Description COMPOSITION: Desloratadine ................................ 5 mg Excipients q.s............................. 1 tablet (Lactose, avicel M101, PVP K30, kollidon CL-M, sodium lauryl sulfate, magnesium stearate, HPMC 606, HPMC 615, PEG 6000, Kollidon VA64, titanium dioxide, talc, indigo carmine lake). DOSAGE FORM: Film coated tablet PRESENTATION: Box of 3 blisters x 10 tablets. PHARMACODYNAMICS: Desno contains the active ingredient desloratadine which is a metabolite of loratadine and an H1-receptor histamine antagonist. After oral administration, desloratadine selectively blocks peripheral histamine H1-receptors. It does not cross the blood-brain barrier and has effects on selective peripheral histamine receptors; therefore, the sedative and parasympathetic properties of desloratadine are very low. PHARMACOKINETICS: Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours. Desloratadine is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89%, bound to plasma proteins, respectively. Plasma protein binding of desloratadine and its metabolite is unchanged in subjects with impaired renal function. The mean elimination half-life of desloratadine is 27 hours. INDICATIONS: For the relief of symptoms of seasonal allergic rhinitis, perennial allergic rhinitis including sneezing, coryza, nasal itching, snuffles. Relief of symptoms of chronic idiopathic urticaria. CONTRAINDICATIONS: Hypersensitivity to any components of the drug. PRECAUTIONS: Do not indicate desloratadine under tablet form to children aged less than 12 years because it is hard to divide the tablet into small doses. Renal and hepatic impairment patients PREGNANCY AND LACTATION: Desloratadine is only indicated to pregnant women if clearly needed and followed the physician's direction. Desloratadine has been detected in breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue from desloratadine therapy taking account the benefit of breast-feeding for the child and the benefit of therapy for the woman. VEHICLE DRIVERS AND MACHINERY OPERATORS: The drug does not affect the ability to drive or operate machinery. INTERACTIONS: Ketoconazole, erythromycin, azithromycin, fluoxetine, cimetidine increase the plasma concentrations of desloratadine. ADVERSE EFFECTS: Uncommon: headache, dryness of mouth, drowsiness, nausea. Rare: hypersensitive reaction, skin rash. Inform your physician about any adverse effects occur during the treatment. OVERDOSAGE: In case of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic treatment is recommended. DOSAGE & ADMINISTRATION: Adults and children aged more than 12 years: oral dose of 1 tablet once daily. Or as directed by the physician. Read the directions carefully before use. Consult the physician for more information. Shelf-life: 24 months from the manufacturing date. Storage conditions: Store in dry places, not exceeding 30oC, protect from light. Specifications: Manufacturer's.


There are yet no reviews for this product.